Erica Bell, PhD

College

College of Medicine

Department/Division

Radiation Oncology

Academic Title

Asst Professor - Clinical

Research Program

Translational Therapeutics

Research Interest

Glioma, Cancer, Brain Cancer, Glioblastoma, DNA Damage, Lung Diseases

Erica Bell, PhD, focuses her research on understanding the mechanisms of radiation and chemotherapy resistance and sensitivity. In particular, Dr. Bell is interested in the identification of novel predictive and prognostic molecular biomarkers, specifically biomarkers that can be exploited therapeutically.

As a member of the world-renowned Translational Therapeutics program, her current field of research is focused on correlative analysis on clinical trial tissue and institutional cohorts including genomic, epigenomic, transcriptomic, metabolomic and proteomic profiling in order to detect novel tumor biomarkers that correlate with treatment efficacy and survival. She is currently performing whole genome profiling on tissue from multiple NRG Oncology trials. Her current disease-site focus for the biomarker research is adult and pediatric brain tumors as well as prostate cancer. Dr. Bell is also the co-inventor of a miRNA-based predictive model for the diagnosis and prognosis of prostate cancer, which has been submitted for patent approval. Additionally, she is focused on characterizing the effects of chromatin remodeling on DNA repair and chemoradiation resistance and sensitivity.

Dr. Bell’s work has appeared in well-respected publications, including the New England Journal of Medicine, JAMA Oncology, Journal of Clinical Oncology, Neuro-oncology, Clinical Cancer Research and Cancer Research. She also has presented her work to professional organizations around the globe, including NRG Oncology, American Society of Clinical Oncology, Society of Neuro-oncology, the World Federation of Neuro-oncology and the American Society for Radiation Oncology.

Education and Background

Office Location

385 Wiseman Hall

410 W 12th Avenue, Columbus, OH 43210

614-366-0845

bell.947@osu.edu

Publications

Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525.

Bell EH, Pugh SL, McElroy JP, Gilbert MR, Mehta M, Klimowicz AC, Magliocco A, Bredel M, Robe P, Grosu AL, Stupp R, Curran W Jr, Becker AP, Salavaggione AL, Barnholtz-Sloan JS, Aldape K, Blumenthal DT, Brown PD, Glass J, Souhami L, Lee RJ, Brachman D, Flickinger J, Won M, Chakravarti A

JAMA Oncol 3 784-792 06/01/2017
Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813.

Chang S, Zhang P, Cairncross JG, Gilbert MR, Bahary JP, Dolinskas CA, Chakravarti A, Aldape KD, Bell EH, Schiff D, Jaeckle K, Brown PD, Barger GR, Werner-Wasik M, Shih H, Brachman D, Penas-Prado M, Robins HI, Belanger K, Schultz C, Hunter G, Mehta M

Neuro Oncol 19 252-258 01/01/2017
Personalized Prognostic microRNA Models for Lower Grade Gliomas.

Fleming J, Bell EH, McElroy JP, Fabian D, Beyer S, Salavaggione AL, Öhlke O, Staszewski O, Prinz M, Grosu A, Chakravarti A

Int J Radiat Oncol Biol Phys 96 S91-S92 10/01/2016
A Mutation and Prognostic Biomarker Study in Grade II and III Gliomas Utilizing a Combined Cohort of NRG Oncology/RTOG 9802 and 9813.

Bell EH, McElroy JP, Fleming J, Timmers C, Chakraborty AR, Salavaggione AL, Chang SM, Shaw EG, Aldape K, Brachman D, Schultz CJ, Shih HA, Curtis M, Hunter GK, Murtha AD, Zhang P, Won M, Mehta MP, Chakravarti A

Int J Radiat Oncol Biol Phys 96 S91 10/01/2016
Proteomic Biomarkers of Grade II and Grade III Gliomas.

Bassett E, Bell EH, Öhlke O, Chen Y, Barnholtz-Sloan J, Fabian D, Beyer S, Salavaggione AL, Staszewski O, Prinz M, Grosu A, Chakravarti A

Int J Radiat Oncol Biol Phys 96 E86 10/01/2016
SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer.

Bell EH, Chakraborty AR, Mo X, Liu Z, Shilo K, Kirste S, Stegmaier P, McNulty M, Karachaliou N, Rosell R, Bepler G, Carbone DP, Chakravarti A

Clin Cancer Res 22 2396-404 05/15/2016
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma.

Buckner JC, Shaw EG, Pugh SL, Chakravarti A, Gilbert MR, Barger GR, Coons S, Ricci P, Bullard D, Brown PD, Stelzer K, Brachman D, Suh JH, Schultz CJ, Bahary JP, Fisher BJ, Kim H, Murtha AD, Bell EH, Won M, Mehta MP, Curran WJ Jr

N Engl J Med 374 1344-55 04/07/2016
Genomic Characterization of Non-Small-Cell Lung Cancer in African Americans by Targeted Massively Parallel Sequencing.

Araujo LH, Timmers C, Bell EH, Shilo K, Lammers PE, Zhao W, Natarajan TG, Miller CJ, Zhang J, Yilmaz AS, Liu T, Coombes K, Amann J, Carbone DP

J Clin Oncol 33 1966-73 06/10/2015
A novel miRNA-based predictive model for biochemical failure following post-prostatectomy salvage radiation therapy.

Bell EH, Kirste S, Fleming JL, Stegmaier P, Drendel V, Mo X, Ling S, Fabian D, Manring I, Jilg CA, Schultze-Seemann W, McNulty M, Zynger DL, Martin D, White J, Werner M, Grosu AL, Chakravarti A

PLoS One 10 e0118745 01/01/2015
Biomarkers usher in era of personalized care for malignant glioma patients.

Chakravarti A, Palanichamy K, Bell EH

CNS Oncol 1 3-6 09/01/2012